Does Your Employer Cover GLP-1? The Opt-In Rule Nobody Explains

The opt-in rule that confuses everyone

When someone says "my insurance doesn't cover Wegovy," the reality is usually more specific: their employer didn't buy that benefit. Commercial health insurance works like a menu — the carrier administers the plan, but the employer picks what's on it. Anti-obesity medications are an optional add-on, and they cost the plan real money. Two people with identical Cigna or BCBS cards can get opposite answers because their employers checked different boxes.

2026 coverage landscape

• Large employers (500+): ~50% cover weight-loss GLP-1s — up sharply from ~18% in 2022, but the trend is fragmenting.
• Small employers: coverage is much rarer — the per-member cost math is harder to absorb.
• The dropouts: some employers who added coverage in 2023-24 are restricting or dropping it after seeing 20-50% pharmacy-spend increases.
• The stricter PA trend: employers keeping coverage are adding requirements — documented lifestyle programs, obesity-medicine specialist prescriptions, re-authorization every 6-12 months.

For insurer-specific rules once your employer opted in, see our coverage guides: BCBS, UnitedHealthcare, Aetna, Cigna, Regence.

How to check your specific plan

• Benefits portal — search the formulary for "Wegovy" and "Zepbound" (weight-loss brands) not just "Ozempic."
• Ask HR directly — "does our plan cover anti-obesity medications?" is a normal benefits question.
• Call the insurer — frame it as "for my specific plan," since coverage varies by employer within the same carrier.
• Open enrollment — if your plan changes carriers or tiers, recheck — coverage status flips at renewal.

If your employer excludes them

Three real paths. First: tell HR. Employer benefit decisions are influenced by employee demand — GLP-1 coverage expansion is being driven partly by workforce requests. Second: manufacturer channels — LillyDirect (Zepbound $299-449) and NovoCare (Wegovy $299-499) are legal cash-pay outside insurance. Third: compounded — licensed telehealth programs deliver compounded semaglutide from $119/month, often cheaper than the copay would have been anyway. See GLP-1 without insurance guide.

Frequently asked questions

Do employers have to cover GLP-1 weight loss drugs?

No — weight-loss medication coverage is an opt-in choice for employer-sponsored plans. The insurer administers the plan, but the employer decides whether anti-obesity drugs are a covered benefit. That's why two people on the same insurance carrier get different answers: their employers chose differently.

What percentage of employers cover GLP-1s in 2026?

Roughly half of large employers cover GLP-1s for weight loss as of 2026 surveys — up significantly from ~18% in 2022, but the trend is fragmenting: some employers are adding coverage while others are dropping it due to cost. Small employers cover them much less often.

Why are employers dropping GLP-1 coverage?

Cost. GLP-1s for weight loss can cost an employer's plan $1,000+ per member per month, and utilization exploded. Employers that added coverage in 2023-2024 saw pharmacy spend jump 20-50% — some responded by adding stricter PA, others by dropping coverage entirely.

How do I find out if my employer covers GLP-1s?

Check your plan's formulary document (usually in the benefits portal), ask HR directly 'does our plan cover anti-obesity medications?', or call the insurer with the question framed to your specific plan — the same carrier covers it for some employers and not others.

What can I do if my employer excludes GLP-1s?

Real options: ask HR about it (employee requests genuinely drive benefit changes — this is how coverage spreads), use the cash-pay channels (LillyDirect $299-449, NovoCare $299-499), or use compounded semaglutide via licensed telehealth at $119-299/month — often cheaper than a covered copay anyway.

Bottom line

The coverage question isn't "does my insurance cover it" — it's "did my employer opt in." If yes, PA is the only real hurdle; if no, $119/month compounded semaglutide is frequently cheaper than the copay would have been anyway.